|
Abstract Objective To evaluate availability and safety of new active- fixation pacing lead. Methods 101 patients underwent pacemaker implantation at our heart center , of them, 25 cases received new pacing lead (new lead group) , including 3 Medtronic 3830 leads , 14 5086MRI leads (atrial and ventricular leads) and 15 Boston Scientific 4471 leads, the others received 76 ventricular active- fixation leads and 58 atrial passive leads (traditional group). Pacing parameters, operation time, duration of exposure, and the time for lead passing through the tricuspid orifice were recorded. Results The pacing threshold, amplitude, impedance, current, and slope were not significant difference between two groups [ (0.62±0.14) vs (0.63±0.17)V, (11.29±4.28) vs (12.74±6.08)mV, (767.68±132.73) vs (815.14±182.46)Ω, (0.77±0.19) vs (0.85±0.33)mA, (2.46±1.07) vs (2.84±1.02), respectively]. The injury current, operative time, exposure time[(3.24± 1.04) vs (3.33 ±1.05)min], and the time for lead passing through the tricuspid orifice (1.36 ±0.57 vs 1.34 ±0.63)were similar in two groups [(6.83 ±1.57) vs (6.61 ±1.87)mV, (44.20 ±4.65) vs (43.42 ±5.55)min, (3.24 ±1.04) vs (3.33 ±1.05) min, 1.36±0.57vs1.34±0.63, respectively]. There was no serious complication during implantation of new pacing lead. A 4471 model lead dislocated completely after operation. There was no significant difference of threshold, amplitude and impedance between two groups at 1- year fol ow- up (al P>0.05). Conclusion The new pacing leads are safety and meet the requirements of pacemaker implantation, without increasing the operative time and exposure time.
|
|
|
|
|
|
